Table 2.
Demographic and clinical characteristics at baseline, 6 months and 12 months
| Baseline | 6 months | 12 months | ||||
|---|---|---|---|---|---|---|
| SITA group (n = 20) | CONT group (n = 20) | SITA group (n = 20) | CONT group (n = 20) | SITA group (n = 20) | CONT group (n = 20) | |
| BMI (kg/m2) | 23.19 ± 0.64 | 24.46 ± 0.63 | 23.11 ± 0.65 | 24.41 ± 0.62 | 23.05 ± 0.67 | 24.27 ± 0.58 |
| Insulin dose (U/day) | 12.0 ± 2.6 | 14.0 ± 2.4 | 11.5 ± 2.5 | 15.2 ± 2.8 | 12.3 ± 2.6 | 18.9 ± 3.4 |
| HbA1c (%) | 6.33 ± 0.20 | 6.94 ± 0.41 | 6.35 ± 0.17 | 7.09 ± 0.43 | 6.48 ± 0.21 | 7.12 ± 0.36 |
| FBG (mmol/L) | 6.68 ± 0.40 | 7.54 ± 0.61 | 6.82 ± 0.42 | 7.62 ± 0.67 | 6.29 ± 0.29 | 7.50 ± 0.63 |
| PBG (mmol/L) | 12.72 ± 1.07 | 14.02 ± 1.36 | 12.45 ± 0.90 | 14.79 ± 1.30 | 11.68 ± 1.19 | 14.90 ± 1.28* |
| ▵BG (mmol/L) | 6.05 ± 1.12 | 5.95 ± 0.92 | 5.63 ± 1.01 | 6.08 ± 1.13 | 5.37 ± 1.26 | 7.22 ± 0.92* |
| FCP (pmol/L) | 479.5 ± 71.2 | 477.1 ± 55.5 | 420.9 ± 59.7 | 522.2 ± 59.7 | 441.3 ± 51.8 | 458.3 ± 43.4 |
| 2hCP (pmol/L) | 1,458.9 ± 200.7 | 1,487.9 ± 175.5 | 1,557.7 ± 191.1 | 1,658.4 ± 184.8 | 1,691.3 ± 220.8 | 1,516.7 ± 150.9 |
| ▵CP (pmol/L) | 979.4 ± 166.2 | 1,010.8 ± 137.2 | 1,136.9 ± 148.5 | 1,136.15 ± 157.3 | 1,250.0 ± 179.7 | 1,058.4 ± 125.8 |
Data presented as mean ± standard error of the mean. *P < 0.05, compared with the insulin alone treatment (CONT) group at baseline. ▵CP, 2‐h postprandial C‐peptide – fasting C‐peptide; 2hCP, 2‐h postprandial C‐peptide; BG, blood glucose; BMI, body mass index, FBG, fasting blood glucose; FCP, fasting C‐peptide; CP, postprandial C‐peptide; HbA1c, hemoglobin A1c; PBG, postprandial blood glucose; SITA, sitagliptin and insulin treatment.